LEXX News & Events

The company said, "Lexaria is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention in San Diego, CA...While new corporate relationships require time to identify areas of common interest and capabilities, including but not limited to technologic compatibility, we also continue to advance our pre-existing corporate relationships. While timelines and closure rates are impossible to predict, Lexaria remains optimistic about its prospects. Of note, most of Lexaria's business discussions are related to the GLP-1 sector and its many applications. Within the GLP-1 sector, Lexaria detected a notable shift in this year's BIO conference to a focus on drug safety and adverse event profiles, given the reality that certain drugs currently under development are approaching practical maximums of weight-loss efficacy. Both in public presentations as well as in our one-on-one meetings, a growing number of pharmaceutical companies are confirming that their focus has shifted towards finding a better balance between weight-loss efficacy, tolerability and safety. The idea that GLP-1 drugs can work effectively at the same time as minimizing unpleasant adverse events is consistent with both Lexaria's mission, and the capabilities of our DehydraTECH technology. In addition, Lexaria is pleased to report that interest in DehydraTECH technology is expanding once again outside of the GLP-1 industry. Lexaria has recently received renewed incoming corporate interest in the DehydraTECH-CBD and DehydraTECH-nicotine sectors where the Company has conducted extensive previous R&D validating the efficacy of the DehydraTECH technology."

Lexaria Bioscience (LEXX) announces that dosing began on schedule on June 14th with Human Pilot Study #7, GLP-1-H26-7, that is evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's (NVO) commercially available Wegovy tablets, over a 5-week duration.

Lexaria Bioscience provides the following update on Animal Study #1 that is evaluating a number of formulation enhancements using both DehydraTECH-semaglutide glucagon-like peptide-1 compositions and DehydraTECH-CBD compositions to explore the potential for additional improved performance as well as stake new intellectual property claims. The Study is on schedule and dosing began on June 10, as planned. Barring any unforeseen interruptions, Study results are currently expected by early September. One of the novel objectives of this Study is to evaluate innovative alternative formulations to SNAC which is currently in use by Novo Nordisk with their oral Rybelsus and Wegovy tablet products. If Lexaria is able to scientifically evidence novel new formulations with similarity or superiority to SNAC performance enhancements, we may be able to establish valuable new proprietary IP and an industry alternative to SNAC that could be of value within the keenly competitive GLP-1 sector. To this end, Lexaria is pleased to report that we have already filed 3 new patent applications that anticipate our latest technological improvements in this area. The Study is utilizing Sprague-Dawley rats with 11 separate Study arms evaluating a number of different novel compositions. Blood samples are being taken at multiple timepoints through an 8-24 hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria will leverage the wealth of study data that we have amassed from previous work by utilizing, proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of improvement. The Study is fully funded from existing corporate resources. Lexaria is also reports that on June 11, the company received its first Australian patent grant in Family #21 - Pharmaceutical Compositions and Methods for Treating Hypertension.